(Snippets from the frontline)
COVID-19/BLM: Don’t forget the vulnerable
Over two decades ago, studies revealed benefit of low-dose aspirin in those with heart disease. The only fault was women were left out of these studies! Oops.
COVID-19 Phase 3 clinical trials determining vaccine effectiveness have started, but will they include the most vulnerable population of older adults, and those of color?
Volunteers have been recruited, and many young adults are coming forward for inoculation. Seniors are reluctant and fearful of contracting this virus, while those of color have been disenfranchised and lost trust in the healthcare system.
Data will be collected, but
pharmaceutical companies do not have to reveal all collected statistics to the public. What?!
The public must demand we see all results. When faulty aspirin studies were scrutinized revealing no women were tested, further assessment was immediately done.
The public has a right to examine all data obtained by pharmaceutical companies in these studies. More eyes will engender public trust, and make sure the vulnerable are not left out.
Gene Uzawa Dorio, M.D.
Leave a Comment